

SOLTA MEDICAL INC

Form 4

January 27, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Nardoci Jeffrey C

(Last) (First) (Middle)

C/O SOLTA MEDICAL, 25881 INDUSTRIAL BLVD.

(Street)

HAYWARD, CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLTA MEDICAL INC [SLTM]

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
VP Worldwide Mktg/GM Surg Supp

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/23/2014		U	V Amount 130,580 (1)	D \$ 2.92	0	D
Common Stock	01/23/2014		M	8,346 (2)	A (2)	8,346	D
Common Stock	01/23/2014		M	14,906 (2)	A (2)	14,906	D
Common Stock	01/23/2014		U	8,346	D \$ 2.92	0	D
Common Stock	01/23/2014		U	14,906	D \$ 2.92	0	D

Edgar Filing: SOLTA MEDICAL INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
				Code	V (A) (D)	Date Exercisable Expiration Date	Title	
Performance Restricted Stock Unit	(2)	01/23/2014		M	8,346	(2) 02/08/2022	Common Stock	8,346
Performance Restricted Stock Unit	(2)	01/23/2014		M	14,906	(2) 02/04/2023	Common Stock	14,906
Employee Stock Option (Right to Buy)	\$ 2.48	01/23/2014		D	68,750	(3) 10/28/2019	Common Stock	68,750
Employee Stock Option (Right to Buy)	\$ 1.91	01/23/2014		D	52,085	(3) 02/08/2020	Common Stock	52,085

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Nardoci Jeffrey C
C/O SOLTA MEDICAL
25881 INDUSTRIAL BLVD.
HAYWARD, CA 94545

VP Worldwide Mktg/GM Surg Supp

Signatures

/s/ Jeffrey C.
Nardoci

01/26/2014

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Includes 107,133 shares deemed acquired pursuant to the grant of restricted stock units ("RSU's") on various dates. The vesting of the
(1) RSU's was accelerated in connection with the merger of the Issuer with Valeant Pharmaceuticals International, a Delaware corporation (the "Merger").

(2) Each performance right represented a contingent right to receive a share of Issuer common stock based on the Issuer's stock price performance. In connection with the Merger, the vesting (thus, the settlement) of the performance right was accelerated.

This option, which had become fully vested and exercisable, was cancelled at the closing of the Merger in exchange for a cash payment
(3) equal to the product of (a) the number of shares underlying this option and (b) the difference between the merger consideration of \$2.92 per share and the exercise price per share of this option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.